Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD22

CD22

Brief Information

Name:CD22
Target Synonym:B-Lymphocyte Cell Adhesion Molecule,SIGLEC2,BL-CAM,Siglec-2,Sialic Acid Binding Ig-like Lectin 2,B-cell receptor CD22,Sialic acid-binding Ig-like lectin 2,T-cell surface antigen Leu-14,CD22,CD22 Molecule,CD22 Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:40
Lastest Research Phase:Approved

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

CD22, CD22 antigen (Predicted), CD22 molecule

Background

The Cd22 gene is conserved in human, chimpanzee, dog, cow, mouse, and frog. 170 organisms, including rat, have orthologs with human gene Cd22. B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Moxetumomab pasudotox HA-22; GCR-8015; CAT-8015 Approved Astrazeneca Plc Lumoxiti United States Leukemia, Hairy Cell Innate Pharma 2018-09-13 Leukemia; Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell Details
Inotuzumab Ozogamicin WAY-207294; PF-5208773; CMC-544 Approved Pfizer Inc, Ucb Besponsa Mainland China Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Pfizer Investment Co Ltd 2017-06-28 Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia; Lymphoma, Large B-Cell, Diffuse; Blast Crisis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RD-102 RD-102 Phase 1 Clinical Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse Details
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) Phase 2 Clinical The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
anti-CD22-CAR-transduced T cells(Southwest Hospital) Phase 2 Clinical Southwest Hospital Leukemia; Lymphoma Details
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Wuhan Bio-Raid Biotechnology Lymphoma, B-Cell; Multiple Myeloma Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) CT-120 Phase 2 Clinical Nanjing Iaso Biotherapeutics Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) Phase 1 Clinical University Of Colorado, Denver, Usa Lymphoma, Non-Hodgkin Details
IMJ-995 IMJ-995 Novartis Pharma Ag Details
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) Hebei Senlang Biological Technology Co Ltd Details
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) Persongen Biotherapeutics Details
BAY-1862864 BAY-1862864 Bayer AG Details
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) Kecellitics Biotech Company Ltd Details
Suciraslimab SM-06; SM-03 Phase 3 Clinical Sinomab Bioscience Ltd Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin Details
TRPH-222 CD22-4AP; TRPH-222; CAT-02-106 Catalent Inc Details
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) Phase 1 Clinical University Of Colorado Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
CART22-cells CART22-cells; JJO686 Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
CD19/CD22 dual-target CAR-T (Yake biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical The University Of Texas Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 2 Clinical Shanghai Ultra-T Immune Therapeutics Co LTD Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Bispecific CD19/22 CAR T cells Phase 2 Clinical Lymphoma, Non-Hodgkin; Lymphoma Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Co Ltd Leukemia, Lymphoid Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) 4SCAR19/22 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
JCAR-018 JCAR-018 Phase 1 Clinical National Cancer Institute, Opus Bio Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University, Shanghai YaKe Biotechnology Co Ltd Hematologic Neoplasms Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) Phase 2 Clinical Kk Women'S And Children'S Hospital Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
UCART-22 UCART-22 Phase 1 Clinical Cellectis Sa Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University, Orca Biosystems Inc Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
GC-022 GC-022; GC-022F Phase 2 Clinical Gracell Biotechnologies (Shanghai) Co Ltd Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University, Shanghai General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
ThisCAR-T-22(Fundamenta Therapeutics) ThisCAR-T-22 Phase 1 Clinical Fundamenta Therapeutics Ltd Lymphoma, B-Cell Details
Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine, Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
JNJ-75348780 Phase 1 Clinical Janssen Research & Development Llc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, B-Cell Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) HX-s001; YTS101; HX-s001/YTS101; HXYT-001 Phase 1 Clinical Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CD19- and CD22 specific CAR (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Leukemia; Lymphoma Details
UCART-20x22 UCART-20x22 Phase 2 Clinical Cellectis Sa Lymphoma, Non-Hodgkin Details
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) Phase 2 Clinical Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
SCRI-CAR22v2 Phase 2 Clinical Seattle Children'S Hospital Leukemia; Lymphoma Details
Epratuzumab-cys-tesirine ADCT-602 Phase 2 Clinical Adc Therapeutics Sa Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message